BR112015022565A2 - composições e métodos para aumentar o potencial terapêutico das células tronco - Google Patents

composições e métodos para aumentar o potencial terapêutico das células tronco

Info

Publication number
BR112015022565A2
BR112015022565A2 BR112015022565A BR112015022565A BR112015022565A2 BR 112015022565 A2 BR112015022565 A2 BR 112015022565A2 BR 112015022565 A BR112015022565 A BR 112015022565A BR 112015022565 A BR112015022565 A BR 112015022565A BR 112015022565 A2 BR112015022565 A2 BR 112015022565A2
Authority
BR
Brazil
Prior art keywords
compositions
stem cells
cells
msc
dramatically
Prior art date
Application number
BR112015022565A
Other languages
English (en)
Portuguese (pt)
Inventor
Reinisch Barbara
Van Den Bos Christian
Rosenbaum Claudia
Schenk Judith
Original Assignee
Lonza Cologne Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Cologne Gmbh filed Critical Lonza Cologne Gmbh
Publication of BR112015022565A2 publication Critical patent/BR112015022565A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
BR112015022565A 2013-03-15 2014-03-13 composições e métodos para aumentar o potencial terapêutico das células tronco BR112015022565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159548.0A EP2777703B1 (en) 2013-03-15 2013-03-15 Compositions and methods for enhancing the therapeutic potential of stem cells
PCT/IB2014/001248 WO2014140930A2 (en) 2013-03-15 2014-03-13 Compostions and methods for enhancing the therapeutic potential of stem cells

Publications (1)

Publication Number Publication Date
BR112015022565A2 true BR112015022565A2 (pt) 2017-07-18

Family

ID=47900872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022565A BR112015022565A2 (pt) 2013-03-15 2014-03-13 composições e métodos para aumentar o potencial terapêutico das células tronco

Country Status (10)

Country Link
US (4) US20160030482A1 (enExample)
EP (1) EP2777703B1 (enExample)
JP (1) JP6399410B2 (enExample)
KR (1) KR102203925B1 (enExample)
CN (1) CN105050597A (enExample)
AU (1) AU2014229502B2 (enExample)
BR (1) BR112015022565A2 (enExample)
CA (1) CA2905650C (enExample)
ES (1) ES2602078T3 (enExample)
WO (1) WO2014140930A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144967A1 (zh) 2018-01-29 2019-08-01 中国科学院动物研究所 一种破坏细胞机械稳态以及促进组织器官的再生修复的方法及其应用
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN108728410B (zh) * 2018-06-19 2020-04-21 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
JP7230409B2 (ja) * 2018-10-02 2023-03-01 カシオ計算機株式会社 判定装置、判定方法及び判定プログラム
BR112021017799A2 (pt) 2019-03-08 2021-11-23 Commw Scient Ind Res Org Célula vegetal, planta ou uma parte da mesma, polipeptídeo de fusão nifd ou produto clivado do mesmo, combinação do polipeptídeo de fusão nifd ou produto clivado do mesmo e um polipeptídeo de fusão nifd que compreende um mtp fundido translacionalmente para um polipeptídeo de nifk (nk) ou um produto clivado de mpp do mesmo, polinucleotídeo, vetor, uso de um polinucleotídeo, método de produção uma planta transgênica, método de produção de semente transgênica, método de produção de farinha, farinha integral, amido, óleo, farinha de sementes ou outro produto obtido a partir de sementes, produto produzido a partir da planta transgênica ou parte da mesma, método de preparação de um produto alimentício, e processo de alimentação de um animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011176A2 (en) 2006-07-21 2008-01-24 Northwestern University Myosin light chain kinase inhibitor compounds, compositions and related methods of use
CN101125146B (zh) * 2007-07-02 2011-05-04 中国药科大学 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂
AU2009208391A1 (en) * 2008-01-31 2009-08-06 Monash University Methods of treating thromboembolic disorders
US8557580B2 (en) 2009-02-20 2013-10-15 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CN102395672A (zh) * 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物
CN103201377A (zh) 2010-11-09 2013-07-10 隆萨科隆有限公司 控制细胞与基质结合的方法
CN102940631B (zh) * 2012-11-02 2015-04-15 清华大学 Blebbistatin在促进干细胞存活和维持干细胞干性中的应用

Also Published As

Publication number Publication date
US20180055888A1 (en) 2018-03-01
AU2014229502B2 (en) 2019-03-14
WO2014140930A9 (en) 2016-01-14
WO2014140930A3 (en) 2014-12-24
CA2905650A1 (en) 2014-09-18
US20160030482A1 (en) 2016-02-04
ES2602078T3 (es) 2017-02-17
JP6399410B2 (ja) 2018-10-03
JP2016510808A (ja) 2016-04-11
KR102203925B1 (ko) 2021-01-19
US20200147142A1 (en) 2020-05-14
CA2905650C (en) 2022-08-23
CN105050597A (zh) 2015-11-11
EP2777703A1 (en) 2014-09-17
WO2014140930A2 (en) 2014-09-18
AU2014229502A9 (en) 2016-06-16
EP2777703B1 (en) 2016-09-14
AU2014229502A1 (en) 2015-09-24
KR20150131324A (ko) 2015-11-24
US20240316111A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
MX2021003726A (es) Particulas de arn que comprenden polisarcosina.
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
PH12013502399B1 (en) Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX362098B (es) El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica.
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
BR112015023646A2 (pt) inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
BR112015022565A2 (pt) composições e métodos para aumentar o potencial terapêutico das células tronco
MX363050B (es) Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune.
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
RU2017120359A (ru) Индукция остеогенеза путем внедрения рнк, кодирующей костной морфогенетический белок (кмб)
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи
EA201592073A1 (ru) Фармацевтические композиции, содержащие коллаген и гиалуронат натрия
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
RU2021135194A (ru) Способы и аппараты для подготовки клеточных популяций для клеточной терапии
BR112013032911A2 (pt) leucotoxina e/d como um novo agente anti-inflamatório e microbicida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements